Decitabine: a historical review of the development of an epigenetic drug

The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vos, Dick, van Overveld, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2005
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103145/
https://www.ncbi.nlm.nih.gov/pubmed/16220311
http://dx.doi.org/10.1007/s00277-005-0008-x
_version_ 1783511990590767104
author de Vos, Dick
van Overveld, Wendy
author_facet de Vos, Dick
van Overveld, Wendy
author_sort de Vos, Dick
collection PubMed
description The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.
format Online
Article
Text
id pubmed-7103145
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-71031452020-03-31 Decitabine: a historical review of the development of an epigenetic drug de Vos, Dick van Overveld, Wendy Ann Hematol Original Article The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis. Springer-Verlag 2005-10-12 2005 /pmc/articles/PMC7103145/ /pubmed/16220311 http://dx.doi.org/10.1007/s00277-005-0008-x Text en © Springer-Verlag 2005 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
de Vos, Dick
van Overveld, Wendy
Decitabine: a historical review of the development of an epigenetic drug
title Decitabine: a historical review of the development of an epigenetic drug
title_full Decitabine: a historical review of the development of an epigenetic drug
title_fullStr Decitabine: a historical review of the development of an epigenetic drug
title_full_unstemmed Decitabine: a historical review of the development of an epigenetic drug
title_short Decitabine: a historical review of the development of an epigenetic drug
title_sort decitabine: a historical review of the development of an epigenetic drug
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103145/
https://www.ncbi.nlm.nih.gov/pubmed/16220311
http://dx.doi.org/10.1007/s00277-005-0008-x
work_keys_str_mv AT devosdick decitabineahistoricalreviewofthedevelopmentofanepigeneticdrug
AT vanoverveldwendy decitabineahistoricalreviewofthedevelopmentofanepigeneticdrug

Ejemplares similares